NIMGenetics is a privately owned Spanish biomedical company specializing in the design and commercialization of products and services for clinical genetic diagnosis. We develop exclusive genomic products and services essentially based on two technologies: microarrays and Next-generation sequencing. We have expanded the value of our high-performance genomic products and services to the international market, becoming a top leader in genomic analysis and human genetic diagnostics. In 2012, NIMGenetics started an internationalization process, being the first targets Mexico and India, and broadening it to LATAM market.
NIMGenetics has a professional scientific and medical multidisciplinary and innovative team with a proven track-record in applying new genomic technologies to medicine and research, and a solid experience in analysis and interpretation of genomic data.
In the field of genomic research on diseases that have social and economic impact, research and development is punctuated by rapid scientific and technological breakthroughs. NIMGenetics continuously evaluates new technologies, to identify and develop those which can be used to design new diagnostic tests whilst, at the same time, improving the existing tests.
Contact details: Enrique Samper Rodríguez President and Chief Executive Officer Paula Villadóniga González Personal Assistant (P.A) Tel. 663913853
NIMGenetics is a leading Spanish company in the area of genetic diagnostics. The company’s president and CEO, Enrique Samper, traces the evolution of NIMGenetics over the last four years, its…
Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is…
Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around…
The European Union’s just-released and first essential medicines list is the latest in a series of measures designed to limit the bloc’s reliance on countries outside its borders and avoid…
The COVID-19 pandemic and subsequent shortages of essential medicines and APIs laid bare Europe’s reliance on suppliers outside its borders. To combat this issue and ensure that Europe is better…
A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared…
Spanish mid-cap Esteve is selling a 26 percent stake in the company to German private investment firm Lubea, a move it says will supply the necessary funds to further pursue…
The latest news from Spanish pharmaceuticals and healthcare, including national champion Esteve’s decision to sell of a quarter of its stock to German private investment firm Lubea; news of pharma’s…
A roundup of the latest news from Spanish pharma, including Almirall’s earnings forecast for 2023; stock price rise and layoffs at Grifols; PharmaMar’s first European approval for its lurbinectedin treatment…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
What major regulatory trends are emerging in Europe and in Spain? As one of the founding partners of a law firm focused uniquely on the life sciences industry, Faus &…
Faus & Moliner Abogados is a Spanish law firm that has been specializing in pharma and life sciences law since 1997. Founding partner Jordi Faus explains how having a comprehensive…
Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate…
See our Cookie Privacy Policy Here
